Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

BACKGROUND: Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Denmeade, SR, Jakobsen, C, Janssen, S, Khan, SR, Garrett, E, Lilja, H, Christensen, S, Isaacs, J
Natura:	Journal article
Lingua:	English
Pubblicazione:	2003

Documenti analoghi

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
di: Janssen, S, et al.
Pubblicazione: (2004)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
di: Denmeade, SR, et al.
Pubblicazione: (2003)

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
di: Janssen, S, et al.
Pubblicazione: (2006)

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
di: Singh, P, et al.
Pubblicazione: (2009)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
di: Lilja, H, et al.
Pubblicazione: (2008)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
di: Botchorishvili, G, et al.
Pubblicazione: (2009)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
di: Haese, A, et al.
Pubblicazione: (2004)

Biology of prostate-specific antigen
di: Lilja, H
Pubblicazione: (2003)

Biology of prostate-specific antigen.
di: Lilja, H
Pubblicazione: (2003)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
di: Bangma, C, et al.
Pubblicazione: (2010)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
di: Vickers, A, et al.
Pubblicazione: (2011)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
di: Evans-Axelsson, S, et al.
Pubblicazione: (2012)

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
di: Dhar, Shanta, et al.
Pubblicazione: (2011)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
di: Vickers, A, et al.
Pubblicazione: (2010)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
di: Vickers, A, et al.
Pubblicazione: (2009)

[Isoforms of free prostate-specific antigen]
di: Haese, A, et al.
Pubblicazione: (2004)

Isoforms of free prostate-specific antigen
di: Haese, A, et al.
Pubblicazione: (2004)

First report of prostate-specific membrane antigen-targeted immunotherapy in prostate cancer: the future is bright
di: Lamb, A, et al.
Pubblicazione: (2018)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
di: Aus, G, et al.
Pubblicazione: (2004)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
di: Lilja, H, et al.
Pubblicazione: (2008)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
di: Hugosson, J, et al.
Pubblicazione: (2003)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
di: Cao, Y, et al.
Pubblicazione: (2002)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
di: Zackrisson, B, et al.
Pubblicazione: (2003)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
di: Vickers, A, et al.
Pubblicazione: (2010)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
di: Becker, C, et al.
Pubblicazione: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
di: Becker, C, et al.
Pubblicazione: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
di: Hugosson, J, et al.
Pubblicazione: (2003)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
di: Vickers, A, et al.
Pubblicazione: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
di: Vickers, A, et al.
Pubblicazione: (2010)

The usefulness of prostate specific antigen density in prostate cancer detection: a Malaysian perspective
di: Shanggar, K., et al.
Pubblicazione: (2010)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
di: Challacombe, B, et al.
Pubblicazione: (2009)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
di: Bruun, L, et al.
Pubblicazione: (2005)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
di: Aus, G, et al.
Pubblicazione: (2003)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
di: Roobol, M, et al.
Pubblicazione: (2009)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
di: O'Brien, M, et al.
Pubblicazione: (2011)

Synthesis of the thapsigargins.
di: Ley, S, et al.
Pubblicazione: (2004)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
di: Ylikoski, A, et al.
Pubblicazione: (2001)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
di: Törnblom, M, et al.
Pubblicazione: (2001)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
di: Harrison, S, et al.
Pubblicazione: (2020)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
di: Brindle, L, et al.
Pubblicazione: (2006)